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Abstract
Chikungunya virus (CHIKV) is an emerging mosquito-borne alphavirus indigenous to tropical Africa and Asia. Acute illness is
characterized by fever, arthralgias, conjunctivitis, rash, and sometimes arthritis. Relatively little is known about the antigenic
targets for immunity, and no licensed vaccines or therapeutics are currently available for the pathogen. While the Aedes
aegypti mosquito is its primary vector, recent evidence suggests that other carriers can transmit CHIKV thus raising concerns
about its spread outside of natural endemic areas to new countries including the U.S. and Europe. Considering the potential
for pandemic spread, understanding the development of immunity is paramount to the development of effective counter
measures against CHIKV. In this study, we isolated a new CHIKV virus from an acutely infected human patient and
developed a defined viral challenge stock in mice that allowed us to study viral pathogenesis and develop a viral
neutralization assay. We then constructed a synthetic DNA vaccine delivered by in vivo electroporation (EP) that expresses a
component of the CHIKV envelope glycoprotein and used this model to evaluate its efficacy. Vaccination induced robust
antigen-specific cellular and humoral immune responses, which individually were capable of providing protection against
CHIKV challenge in mice. Furthermore, vaccine studies in rhesus macaques demonstrated induction of nAb responses,
which mimicked those induced in convalescent human patient sera. These data suggest a protective role for nAb against
CHIKV disease and support further study of envelope-based CHIKV DNA vaccines.
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Introduction
Chikungunya virus (CHIKV) is an enveloped, single-stranded,
positive-sense RNA virus that belongs to the family Togaviridae,
genus Alphavirus, and is part of the Semliki Forest virus antigenic
complex [1,2,3,4]. CHIKV has been responsible for unprecedent-
ed, explosive outbreaks during 2004 and 2007 in India and the
Indian Ocean islands [2,4,5,6,7]. These outbreaks represent the
largest documented cases associated with the virus [8]. Chikungu-
nya fever, the disease caused by CHIK xV, was first recognized in
epidemic form in East Africa in 1952-1953 [3,9] and the viral agent
was first isolated at that time from the blood of a febrile patient in
Tanzania [9]. In the local Swahili dialect, ‘‘Chikungunya’’ means
‘‘stooping’’ or ‘‘bending’’, which describes the physical position
often assumed by CHIKV-infected patients [3,9,10]. Since that
time, CHIKV has been identified as the agent responsible for major
epidemics in both Africa and Southeast Asia and continues to be a
re-emerging agent of great interest to public health [1,11,12,13].
Despite its importance as an emerging virus and potential biological
weapon, there are no specific licensed vaccines or antiviral
treatments for Chikungunya.
Currently, CHIKV is geographically distributed from Africa
through Southeast Asia and South America and is principally
transmitted to humans through Aedes mosquitoes [2,14]. Recently, a
mutation in the CHIKV envelope (E1-A226V) was found to be
directly responsible for the significant recent increase in CHIKV
infectivity, and studies confirmed that this single amino acid
substitution can influence vector specificity. This finding provides a
plausible explanation of how this variant virus caused an epidemic
in a region lacking the normal insect vector Ae. Aegypti [15,16].
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11While Chikungunya is not typically associated with human
mortality, epidemics often present public health threats due to
substantial morbidity, suffering, and loss of economic productivity.
The incubation period of the virus ranges between 1–2 weeks and
infected individuals usually experience an acute illness with fever,
headache, rash, nausea, vomiting, incapacitating polyarthralgia,
severe muscle pain, and joint stiffness [17]. The most prominent
clinical feature of CHIKV disease is arthralgia, which can be
debilitating and prolonged [5,17,18,19,20]. Though the patho-
genesis of the virus in humans is not exactly clear, recent findings
of CHIKV infection in muscle tissue and macrophages could
explain some features of its clinical manifestations
[12,18,21,22,23]. Due to these characteristic clinical symptoms
of infection, outbreaks of CHIKV have devastating public health
and economic effects.
The first reported outbreak of Chikungunya occurred on Lamu
Island, Kenya, in 2004. Later the virus spread to La Reunion
Island, infecting more than two hundred thousand individuals
[11], then to other islands in the Indian Ocean [24], and then
finally into India in 2006 [25]. Furthermore, the La Reunion
isolate outbreaks were associated with unexpected morbidity [26].
Importantly, exposed travelers returning from the affected areas to
Europe, the US, Canada, Hong Kong, and numerous other
countries have carried the virus into these new niches where the
imported cases were subsequently identified [8]. Although these
instances of viral importation were effectively controlled, they
serve as a reminder of how easily this agent could be introduced
and spread into new geographical locations including industrial-
ized nations.
Thus far, while several vaccines have been developed against
this disease, such as a formalin inactivated vaccine [27], a virus-
like particle vaccine [28] and a live attenuated vaccine [29], none
have advanced to clinical development and therefore illustrate an
important area of need. Recently, a novel consensus-based DNA
vaccine was developed by our laboratory and reported to be
immunogenic in mice [30], inducing both measurable cellular and
humoral immune responses. However, the neutralizing and
hemagglutination-inhibiting antibody responses were not exam-
ined. While nAb to CHIKV during natural infection in humans
are not well understood, recent sero-surveys during outbreaks
suggest a protective role for prevention of replication
[23,28,30,31,32]. Furthermore, prior infection is thought to be
protective against subsequent CHIKV infection. Therefore, by
examination of nAb titers during natural infection in humans, a
benchmark for vaccine development in this study, we aimed to
establish a correlation with these responses and protection.
Accordingly, we isolated a new viral isolate from an acutely
infected patient, and termed PENN CHIKV-2008 (PC-08), and
characterized its biology in mice, and also used it to develop an in
vitro neutralization assay. Furthermore, we modified our previous
DNA vaccine to optimize for the capacity of neutralization by
designing a single consensus envelope DNA vaccine construct
expressing all three envelope proteins. We compared its effects in
mice with a CTL-only-inducing Capsid vaccine in a challenge
model. Finally, we compared in non-human primates vaccine-
induced immune responses with human CHIKV convalescent sera
as a measure of protective immunity.
Materials and Methods
Ethics statement
Samples used in the study were provided by Regional Medical
Research Center (RMRC), Indian Council of Medical Research
(ICMR), Port Blair, India and Sri Ramachandra Medical College
& Research Institute (SRMC&RI), Chennai, India. These samples
were previously obtained with proper informed consent at the
respective institutions. The collected samples were coded and
stored. The samples do not contain identifying information
regarding the patients that donated the samples and under an
agreement between the collaborating institutions that determined
at no point was the key decoding patient data disclosed to the
investigators performing the assays. The study was reviewed by the
respective Institutional Human Ethical Committees and approvals
were obtained. The de-identified samples were transported to
University of Pennsylvania, PA, USA following EHRS guidelines
and after obtaining the CDC import permit to Import or
Transport Etiologic Agents, Hosts or Vectors of Human Disease
(Permit # 2008-03-027). Appropriate practices and procedures as
defined in the Biosafety in microbiological and biomedical
laboratories (US Dept. of Health and Human Services) were used
in sample handling. Samples were stored at 280uC in a bio safety
level-3 (BSL-3) facility at the University of Pennsylvania, PA, USA.
Primate studies were conducted by the subcontract at Bioqual
Inc, MD. The animal management program of this institution is
accredited by the American Association for the Accreditation of
laboratory Animal Care and meets NIH standards as outlined the
in the Guide and care and use of laboratory animals. This
institution also accepts as mandatory PHS policy on Humane
Care of Vertebrate Animals used in testing, research and training.
Cell culture and animals
Vero 76 (ATCC CRL-1587) and RD (ATCC CCL-136) cells
were cultured in complete medium (Eagle’s Minimum Essential
Medium) containing 10% fetal bovine serum, 1 mM glutamine,
1 mM sodium pyruvate, 100 U/ml penicillin and 100 mg/ml
streptomycin. Cells were incubated in a 5% CO2 humidified
incubator at 37uC [33]. 8-week-old female BALB/c mice (Jackson
laboratories, Indianapolis, IN) were used in these experiments. All
animals were housed in a temperature-controlled, light-cycled
facility in accordance with the guidelines of the National Institutes
of Health (Bethesda, MD, USA) and the University of Pennsylva-
nia Institutional Animal Care and Use Committee (IACUC).
Author Summary
Chikungunya fever epidemics are sustained by a cycle of
human-mosquito-human transmission, with the epidemic
cycle being similar to those of dengue and urban yellow
fever. While the threat of a pandemic continues to engage
the public’s attention, the peculiar problems associated
with the more immediate and very real seasonal epidemics
are also worthy of consideration. Specifically, there are
limited viral strains that have been characterized and
available for laboratory study as well as limited knowledge
of immune responses induced to the virus. In this study,
we isolated CHIKV virus from an acutely infected human
patient and used this new virus to develop a neutralization
assay and a challenge stock, which is effective in a mouse
model. Furthermore, we analyzed the ability of an
envelope-based synthetic DNA-based vaccine to impact
viral disease in the mouse model and to generate
protective levels of immune responses in nonhuman
primates. We observed that this novel vaccine approach
generated protective levels of immune responses in both
mouse and non-human primate models. We believe that
these studies advance the field of Chikungunya vaccine
research as well as the study of immune protection to
CHIKV.
Chikungunya DNA Vaccination
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Bioqual, Inc, Rockville, MD 20850. The experiments reported
herein were conducted according to the principles set forth in the
Guide for the Care and Use of Laboratory Animals, Institute of
Laboratory Animal Resources, National Research Council,
Department of Health and Human Services (DHHS) Publication
number NIH-86-23 (1985).
DNA vaccine construction and expression
The CHIKV DNA constructs pCHIKV-E1, pCHIKV-E2, and
pCHIKV-Capsid have been previously described [30]. The
combined CHIKV-envelope construct was designed with the
structural genes E3, E2 and E1 linked together in a single
construct with furin cleavage sites between the individual genes
[34]. The consensus gene sequences were constructed using the
predicted consensus sequences from the sequences available in the
NCBI Genbank database and designated as pMCE321. We note
that while the 6K protein is also a structural constituent of
envelope, we did not include it in our vaccine construct because
we sought to create a minimal vaccine construct capable of
inducing broadly protective immune responses. The primary role
of 6K is postulated to function in the selection of lipids that
interact with the transmembrane domains of the glycoproteins
[35]. Consensus sequences were optimized for Env expression,
including codon and RNA optimization (GeneArt, Regensburg,
Germany), a novel leader sequence was added [36] as were furin
cleavage sites to facilitate Env processing as previously published
[34] and inserted into the pVax1 expression vector (Invitrogen,
CA) and designated as pMCE321. DNA preparations were made
at Aldevraon (Forgo, ND), as previously described and formulated
at 10 mg/ml in water.
Expression of pMCE321 was verified by immunoblotting and
immunofluorescence. Vero and RD cells (1610
6cells) were
transfected with pMCE321 constructs using the Fugene transfection
method (Roche, Indianapolis, IN). Forty-eight hours post-transfec-
tion, proteins were isolated using cell lysis buffer, fractionated on
SDS-PAGE (12%), and transferred to nitrocellulose using iBlot Dry
Blotting System (Invitrogen, CA, USA). Immunodetection was
performed using SNAP i.d. Protein Detection System (Millipore,
MA, USA) with specific mouse antiserum and the expressed
proteins were visualized with horseradish peroxidase-conjugated
goat anti-mouse IgG using an ECL detection system (Amersham
Pharmacia Biotech, Piscataway, NJ) [33].
Immunofluorescence and histopathology
For immunofluorescence, Vero cells (2610
5 cells) were seeded in
2-chamber tissue culture treated glass slides (BD Falcon, MA, USA)
and transfected with pVax1-E1, pVax1-E2, and pMCE321 vaccine
constructs or control pVax1 vector. Forty eight hours post-
transfection, cells were fixed with 2% paraformaldehyde, blocked
with Glycine/BSA, and then incubated overnight at 4uC with
mouse anti-Env IgG antibodies (1:500 dilution). Excess antibodies
were washed off and the secondary antibody AlexaFluor 488-anti
mouse IgG (Invitrogen, Molecular Probes, USA) was added and
incubated for 2 hours at 37uC. The cells were counter stained with
DAPI for visualizing the nucleus and fixed with fluoromount G
(Electron Microscopy Sciences, PA, USA). The confocal images
were acquired with Zeiss LSM510 META NLO Laser Scanning
Confocal Microscope with Two Photon Excitation at the
Biomedical Imaging Core, University of Pennsylvania, PA, USA.
For histopathology studies, naı ¨ve and CHIKV DNA vaccinated
mice, challenged with the CHIKV isolate, were bled and sacrificed
on day 14 p.i. Tissue samples (brain, heart, lung, liver, and kidney)
were collected and fixed in 10% buffered formalin solution for
24 h, and then stored in 70% ethanol prior to embedding,
sectioning, and staining using hematoxylin and eosin (H&E) stain
[23,37].
CHIKV patients
CHIKV-infected patient sera samples were obtained from
ICMR, Port Blair, India and SRMC&RI, Chennai, India. The
number of days from onset of illness to sampling ranged from 1 to
14 d. All cases had complained of fever with median duration of
3–5 d. Other common symptoms included Chills and Rigors
(23%), myalgias (6%), gastrointestinal symptoms of diarrhea,
abdominal pain (20%), vomiting (20%), severe joint pain (3%) and
headache (13%) (Table 1).
CHIK virus extraction
The isolation of virus from patient sera was carried out in Vero
cells grown to 90–95% confluence in Eagle’s complete medium
(MEM) in T-25 tissue culture flasks (BD Falcon, USA). Patient
serum (100 ml) was mixed with MEM (400 ml), adsorbed onto the
cell culture (after removing the growth medium) for 2 hrs at 37uC,
and then replenished with complete growth medium following
washing with MEM. The inoculated cells were incubated at 37uC
with 5% CO2 for 5 to 7 days and monitored daily for the
development of cytopathic effects (CPE). When CPE was observed
in more than 90% of the cells, the flasks were frozen at 280uC,
freeze–thawed five times to facilitate cell lysis and virus release,
and then centrifuged at 3,000rpm for 10 min to remove cellular
debris. The isolate was then passaged five times in Vero cells,
titrated, and stored at 280uC. The virus stock was designated as
PC-08 (PENN CHIKV strain - 08).
Viral RNA from patient serum was extracted using QIAamp
Viral RNA mini kit according to manufacturer’s instructions
(Qiagen Inc, Valencia, CA). A one-step RT-PCR test was carried
out using Qiagen One step RT-PCR kit on a block thermo cycler
(PTC-100, MJ Research, Waltham, MA, USA); 5 pmoles of each
primer (CHIK-forward 59-TATCCTGACCACCCAACGCTCC-
39 and CHIK-reverse 59-ACATGCACATCC CACCTGCC-39
amplify a 305 bp region within the gene coding for the viral
envelope protein E2) were used with 10 ml 5X RT PCR buffer,
2 ml dNTP mix, 5 ml Q solution, 1 ml enzyme mix, 25 ml water,
and 5 ml extracted RNA for a total reaction volume of 50 ml [38].
Thermocycler conditions were as follows: 50uC for 30 min, 94uC
for 2 min, then 40 cycles of 94uC for 15 s, 55uC for 30 s and 68uC
for 2 min 20 s with a final extension at 68uC for 5 min. PCR
products were purified by gel extraction (Qiagen Inc, Valencia,
Table 1. Clinical observation in Chikungunya patients.
Symptoms # of Patients %
Fever 30 100
Chills and Rigors 7 23
Head Ache 4 13
Myalgia 2 6
Rash/Hemorrhage 0 0
Severe Joint pain 1 3
Abdominal pain 6 20
Vomiting 6 20
RT-PCR positivity 13 43
doi:10.1371/journal.pntd.0000928.t001
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Sequencing Facility.
DNA immunization and Chikungunya viral challenge
studies
BALB/c mice (n=14/each group) were immunized with the
pCHIKV-Capsid, the pCHIKV-Envelope (pMCE321) constructs,
or control pVax1 (25 mg) 3 times at 2-week intervals, according to
a standard DNA immunization protocol. All injections were
delivered into the quadriceps muscles in a total volume of 25 ml
followed by i.m. electroporation (Inovio Biomedical Corporation,
Blue Bell, PA) as described previously [30,39]. After the last
immunization, 4 mice from each group were sacrificed for
immunology assays (IFN-c and Abs ELISA), while the remaining
mice (n=10) were used for the challenge studies.
Mice were challenged with 7 log10 PFU of the CHIKV isolate
(PC-08) by intranasal infection (i.n.) in a total volume of 25 ml and
animals were checked daily for clinical signs of infection, such as
lethargy and hind limb weakness. Additionally, body weight was
monitored [17,31,40,41]. Animals were then sacrificed either 14
days p.i. or earlier if a weight loss of more than 30% was observed.
Rhesus macaque studies
Non-human primate studies were conducted under a contract at
Bioqual Inc, MD. The animal management program of this
institution is accredited by the American Association for the
Accreditation of Laboratory Animal Care and meets NIH
standards as set in the guide for the Care and Use of Laboratory
Animals. This institution also accepts as mandatory the PHS
policy on Humane Care of Vertebrate Animals used in testing,
research and training. Animals were allowed to acclimate for at
least 30 days in quarantine prior to any immunization. Four rhesus
macaques were immunized at weeks 0, 4, and 8 with 1 mg/
construct (at a concentration of 10 mg/ml) of CHIKV envelope
(pMCE321) and 3 rhesus macaques were immunized with pVax1
vector. DNA was delivered into the quadriceps muscle (intramus-
cularly (i.m.) followed by in vivo electroporation as previously
described [39]. Animals were bled every 2 weeks. Five ml of blood
was collected for serum studies and ten ml of blood was collected
in EDTA tubes, and peripheral blood mononuclear cells were
isolated by standard Ficoll-Hypaque centrifugation and resuspen-
sion in complete culture medium (RPMI 1640 with 2 mM/liter L-
glutamine, 10% heat-inactivated fetal bovine serum, 100 IU/ml
penicillin, 100 mg/ml streptomycin, and 55 mM/liter b-mercap-
toethanol). Red blood cells were lysed with ammonium chloride-
potassium (ACK) lysis buffer (Invitrogen, CA).
Neutralization antibody (nAb) and Hemagglutination (HI)
assays
The 50% tissue culture infectivity dose (TCID50) was calculated
and a standard concentration of virus was used for the micro-
neutralization test throughout these studies. Microneutralization
assays were performed with human patient samples as well as
using the mouse sera from pCHIKV-E1/pCHIKV-E2/and
pCHIKV-Env (pMCE321) immunized animals, as described
previously [42]. Briefly, the patient, mouse, or monkey sera were
serially diluted in MEM (1:10 to 1:10,240) and incubated with an
equal volume of CHIKV (100 TCID50)a t3 7 uC. After 90 min, the
virus-serum mixture was added to a monolayer of Vero cells
(100,000 cells (for patient and mouse samples) and 15,000 cells (for
monkey samples) per well) in a 96-well flat bottom plate and
incubated for 5 days at 37uC in a 5% CO2 incubator. The highest
titer at which no CPE was observed was recorded as the nAb titer.
HI assays were performed as described previously for
Arboviruses [43] and CHIKV virus isolate was used as the
antigen. Kaolin-treated sera from human patient samples or
immunized mice were diluted and tested at serial 2-fold dilutions
from 1:10 to 1:1,280 at pH 6.3, using eight hemagglutination
(8HA) units of antigen (CHIKV) and 0.4% goose erythrocytes.
The highest dilution of the serum that inhibited hemagglutination
was recorded as the HI titer. HI titers greater than or equal to 20
were considered positive [41].
IFN-c ELISpot assay and ELISA
ELISpot assays were performed as previously described [33,39].
Briefly, 96-well ELISpot plates (Millipore) were coated with anti-
mouse IFN-c capture Ab (R&D Systems) and incubated for 24 h
at 4uC. The following day, plates were washed with PBS and
blocked for 2 h with 1% BSA. Two hundred thousand splenocytes
from the pMCE321 Env-immunized mice were added to each well
and incubated overnight at 37uCi n5 %C O 2 in the presence of
media alone (negative control), media with Con A (positive
control), or media with peptide pools (10 mg/ml) consisting of 15-
mers overlapping by 9 amino acids and spanning the length of the
appropriate protein. After 12 h, the cells were washed and then
incubated for an additional 24 h at 4uC with biotinylated anti-
mouse IFN-c Ab (R&D Systems, Minneapolis, MN). Streptavidin–
alkaline phosphatase was added to each well after washing and
then incubated for 2 h at room temperature. The plates were
washed, and then 5-bromo-4-chloro-39-indolylphosphate p-tolui-
dine salt and nitro blue tetrazolium chloride (chromogen color
reagent; R&D Systems) were added to the wells. Lastly, the plates
were rinsed with distilled water, dried at room temperature, and
spot forming units (SFU) were quantified by an automated
ELISpot reader (CTL Limited). For each sample, the raw values
were normalized to SFU per million splenocytes.
CD8
+ T-cell depletion studies were carried out following
immunomagnetic cell separation. Dynabeads (Dynal Biotech)
monkey CD8 (clone BW135/80) was used as the method for
separation, resulting in 90% depletion in 20 min using 1610
7
beads/ml for 2.5610
6 splenocytes. Depletion was conducted as
described by the manufacturer. The negatively isolated cells
(CD8
+ T cell depleted) were transferred to a second tube for
further use in the ELISpot assays [44,45].
The proinflammatory cytokines levels following CHIKV infec-
tion were determined in the culture medium using a commercially
available ELISA kit following the manufacturer’s instructions (R&D
Systems Inc, MN). All samples were analyzed in triplicate [33].
Statistical analysis
Data was collected from cellular assays and presented as the
mean +/2 standard deviation which was calculated from triplicate
wells of pooled samples from each experimental group. Prior to all
statistical analysis, the normality of the data was confirmed with
Levine’s test. Analysis between groups was performed using
independent samples t-test. Comparisons among three groups
were performed with ANOVA with a post-hoc Fisher’s Least
Significant Difference (LSD) test to correct for multiple compar-
isons between groups. In each case, p#0.05 was considered to be
significant. All statistical analysis was carried out using the
Statistical Package for the Social Sciences (SPSS).
Results
Clinical observation in CHIKV patients
The clinical manifestations caused by the Chikungunya
outbreaks in 2005 to 2007 appeared varied and somewhat
Chikungunya DNA Vaccination
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particular, the hemorrhagic tendency of CHIKV infections is not
as predominant as that of past outbreaks [46]. Accordingly, we
sought to study serum samples from the recent CHIKV outbreaks
and characterize viruses and the humoral responses from acute
and convalescent sera of infected patients. During the recent
outbreak in India, serum samples were regularly collected from
patients with complaints of high fever, chills, headache, vomiting
and severe abdominal pain (outpatient department, Sri Rama-
chandra Medical Centre, Chennai, India & at Regional Medical
Research Centre (ICMR), Port Blair, India). From this population,
thirty patient samples suspected for CHIKV were randomly
selected and included in this study; all of the 30 patients from the
outbreak area experienced fever lasting 2–15 days with high-grade
temperature (38uCt o4 0 uC), and in some patients (23%)
accompanied by chills and rigors. Vomiting and abdominal pain
(20% of the patients) as well as headache (13% of cases) was also
observed. While myalgia or joint pain was seen only in 3% of the
patients, rashes or hemorrhages were not observed in this patient
population. Furthermore, sore throat and retro-orbital pain as
seen in other common viral infections was not prominent in this
outbreak. A summary of the clinical and laboratory observations
in this CHIKV-infected patient population is listed in Table 1.
Importantly, 13 samples (43%) were RT-PCR positive to CHIKV
primers demonstrating that some contained Chikungunya virus.
Isolation and identification of CHIKV from patient serum
While samples collected during the first 48–72 h of infection are
typically ideal for virus isolation [28,37], we were able to isolate
CHIKV successfully from RT-PCR positive and symptomatic
patient samples collected at the 3–4 days post CHIKV infection.
Isolation of virus from the serum of a CHIKV positive patient who
had a high-grade fever (40uC) lasting for 2 days was verified by the
observance of massive cell death (Cytopathic effect: CPE) in Vero
cells and by RT-PCR (Fig. 1). As seen in Fig. 1A, the isolated virus
induced CPE indicating the presence of infectious CHIKV and
successful virus production. To further confirm the identity of the
virus that caused CPE, we extracted RNA from the infected cell
culture supernatantandperformeda one step RT-PCRto amplify a
part of the CHIKV E2 gene by reverse transcriptase PCR (Fig. 1B)
and electron micrographs of CHIKV viral isolates (Fig.1C) [38].
The E2 gene was selected as the target region for the RT-PCR
because this gene shows a high degree of divergence among the
alphaviruses [2] and harbors virus-specific nucleotide stretches
suitable for primer design. The sequences from the reaction
amplicons were then analyzed via a Genbank BLAST search and
Figure 1. Isolation and identification of CHIKV. The microphotographs show normal uninfected Vero cells (A) and the Vero cells infected with
CHIKV virus isolate. CHIKV infection in Vero cells causes characteristic foamy cytopathic effect (CPE) 48 hours p.i. as seen with the isolate. (B) RT-PCR
analysis of CHIKV viral isolates. Agarose gel photograph showing the RT-PCR amplified product (305 bp) of the CHIKV positive patient isolates (Lane
1&2). The uninfected negative control (Lane 3) shows no amplification. (C) Electron micrographs of CHIKV viral isolates (D) Phylogenetic Tree
generated with E2 amplicon from CHIKV Isolate. * Indicates the PC-08 CHIKV strain.
doi:10.1371/journal.pntd.0000928.g001
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virus was designated as PC-08 (PENN CHIKV strain-2008).
Construction and expression of CHIKV envelope vaccine
Previous studies from our laboratory using the envelope E2 and
E1 DNA vaccine constructs showed the induction of cellular and
humoral responses invaccinated mice [30]. In the present report, we
modified the previous vaccine to optimize its capacity for induction
of neutralization Abs by designing a single consensus envelope
vaccine construct that expresses all three of the CHIKV envelope
glycoproteins (E3+E2+E1). Consensus sequences were optimized for
expression,includingcodonandRNAoptimization[30,47]insertion
ofa novel leadersequence[36] aswell as furincleavagesitesbetween
envelopes to facilitate envelope processing as previously reported
[34] and inserted into the pVax1 expression vector and verified by
sequencing and designated as pMCE321 (Fig. 2A).
Expression of the pMCE321 vaccine constructs in vitro was
verified by immunoblotting and immunofluorescence techniques.
The vaccine constructs expressed strongly in the transfected BHK-
21 and Vero cells and the envelope glycoproteins were detected in
the pMCE321 transfected lysates by Western blot using envelope
E1 antiserum (Fig. 2B). Further, to evaluate the expression of
envelope proteins immunofluorescence techniques were per-
formed with pMCE321 immunized sera in Vero cells transfected
with pVax1, pCHIKV-E1, pCHIKV-E2 or pMCE321. Immuno-
fluorescence showed envelope staining of the expressed proteins in
the cytoplasm, which strongly suggested immune reactivity to each
envelope component of the fusion protein (Fig. 2C). Further, to
visualize the expression of pMCE321, pCHIKV-E1 and
pCHIKV-E2, we performed a parallel FACS analysis from
transfected cells, and studied the surface expression of envelope
proteins. Interestingly, the pCHIKV-E1 and E2 expression profile
was almost identical (Fig. 2D). Unlike E1 and E2 sera expression,
pMCE321 sera respond to strong envelope expression in
transfected cells. These findings demonstrated the ability of the
pMCE321 construct to potently express in mammalian cells and
that the Abs induced by these constructs were able to react with
the individual envelope glycoproteins E1 and E2.
Figure 2. Construction and characterization of CHIKV DNA vaccine. (A) Schematic representation of pMCE321 construct. The flanking
enzyme sites used for cloning, Kozak expression element, CMV promoter, human IgE-leader, CHIKV fusion gene (E3-E2-E1), and cleavage sites (CS) are
indicated and were cloned into the pVax1 vector. (B) Expression of pMCE321 constructs was confirmed in vitro using Envelope-E1 antiserum for the
Western blot of CHIKV envelope antigens expressed in Vero and BHK-21 cells by Western blotting. Arrows indicate the positions of E1 protein
expression. (C) Immunofluorescent assay showing staining of Vero cells transfected with pCHIKV-E1, pCHIKV-E2, or pMCE321 constructs and transient
expression of the envelope proteins. (D). FACS analysis of envelope expression in transfected cells (0.5610
6 cells). Vero cells were transfected with
indicated constructs and stained with anti-Env sera raised in mice, followed by staining with secondary PE-conjugated anti-mouse IgG antibody as
indicated. Two representative FACS histograms are shown.
doi:10.1371/journal.pntd.0000928.g002
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in mice
The ability of pMCE321, to induceCD8
+ CTL responses in
mice after three immunizations was determined by IFN-c ELISpot
assay. Expression of all three of the envelope glycoproteins from
the single DNA vaccine construct induced detectable cellular
immune responses against CHIKV envelope specific peptide pools
(Fig. 3A). The results of the IFN-c ELISpot assay 1 week following
the third i.m. immunization (mean count, 1,6136117) for
pMCE321 against both peptide pools showed strong cellular
immune responses to administered envelope Ag in contrast to the
control. pCapsid- or pVax1-immunized mice showed no envelope-
specific Ag-specific responses at any point during the study.
Capsid-specific T cell responses were induced to the Capsid
vaccine. Because of increased T cell responses to the combined
CHIKV-Envelope vaccine observed in mice, we anticipated that
the Ab responses to combined envelopes would be similarly
increased. To examine this, sera collected one week after each
immunization were tested by ELISA to detect the induction of
Envelope-specific IgG. Interestingly, mice immunized with the
pCME321 complex displayed significantly higher levels of
envelope-specific serum IgG than mice immunized with E1, E2
or E3 alone (Fig. 3B). As expected, the control plasmid, pVax1 did
not elicit any detectable Ab responses as determined by ELISA.
The combination of CHIKV envelope glycoprotein genes into
one vaccine construct, pMCE321, induced measurable levels of
neutralizing and HI antibodies which are significantly greater than
responses induced by pCHIKV E1 and E2 constructs alone
(Fig. 3C–D; p,0.001). Interestingly, we also observed that the E2
and E1 constructs when delivered individually were able to induce
high levels of neutralizing Ab responses or HI titers respectively,
but not both showing segregation of these functions. Importantly,
the pMCE321 construct was able to drive both neutralizing and
HI Ab responses at levels higher than either construct on its own.
Taken together, these data demonstrate that immunization with
the pMCE321 DNA vaccine induced both cellular and humoral
immunity in mice.
We next addressed whether levels of CHIKV vaccine-elicited
immunity were able to confer protective immunity by virtue of its
cellular and neutralizing/HI Ab responses in mice. A virus
challenge study was conducted to assess protective efficacy of the
pMCE321 envelope vaccine in comparison with a CHIKV-
Capsid vaccine which induced cellular responses, but no
neutralization or HI responses. CHIKV-challenged mice were
monitored daily for 14 days p.i. and outcome of the challenge was
evaluated based on the common signs of Chikungunya infection in
mice such as reduction in body weight, survival, lethargy, and hind
limb weakness reported in previous studies [31,41]. A recent study
by Ng et al., strongly suggested that proinflamatory cytokines such
as IL-1b, TNF-a and IL-6 are biomarkers that have utility in
measuring disease severity during CHIKV viral infection [48].
Therefore we also analyzed the production of these pro-
Figure 3. CHIKV DNA vaccination induces strong immunity in mice. BALB/c mice were immunized three times, each 2 weeks apart, with
25 mg pVax1 vector or pMCE321-Env and sacrificed 1 week after the 3
rd immunization. (A) Splenocytes from immunized animals were harvested and
cultured overnight in the presence of peptide pool matrix spanning the Envelope protein (pool-1 & pool-2) and the IFN-c response to each pool was
measured by ELISpot as described in the Materials and Methods. Values represent the mean and standard deviation of triplicate wells and are
representative of three independent experiments. (B) Systemic anti-Env IgG levels after DNA immunization. Each group of inbred BALB/c mice (n=4)
was immunized with indicated vaccines. Mice were bled 1 week after each immunization, and then sera were diluted to 1/100 for reaction with
CHIKV-Env. OD was measured at 450 nm. Values and bars represent mean (n=4) and the SEM. (C and D) Quantification of CHIKV specific neutralizing
and HI titer in sera from DNA immunized mice (pVax1/pCHIKV-E1/pCHIKV-E2 and pMCE321) to CHIKV. The nAb titers are plotted as the highest
dilution of serum that resulted in at least 50% inhibition of CPE. The highest dilution of the serum that inhibited hemagglutination was recorded as
the HI titer. Similar results were observed in three independent experiments with at least n=4 per group for each experiment.
doi:10.1371/journal.pntd.0000928.g003
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infection and compared the levels to naı ¨ve-uninfected mice.
Neither IL-6 nor TNF-a were detected in significant amounts in
naı ¨ve mice; conversely, the production of IL-6 and TNF-a in
CHIKV-infected mice (virus) was significantly greater than that in
naı ¨ve mice (Fig. 4A–B). Similarly, secretion of proinflammatory
mediators including IL-6 and TNF-a was measured in vaccinated
mice and found to be strongly activated in pCapsid-immunized
mice. In contrast remarkably lower levels were detected in
pMCE321-immunized mice (Fig. 4A–B) (p,0.001 versus pCap-
sid). These data suggest that CHIKV Envelope DNA immuniza-
tion, and not Capsid vaccination, was more effective in minimizing
the secretion of proinflammatory cytokines that are commonly
associated with viral pathology.
Further, signs of disease in the naı ¨ve and vaccinated mice
infected with the CHIKV isolate were detected and all mice
showed a reduction in body weight for a period of 3 days p.i.
However, after this initial period, pMCE321-immunized animals
exhibited a restoration in body weight on average when compared
with either naı ¨ve or Capsid-vaccinated animals. While none of the
animals died naturally due to infection, the Capsid-immunized
and naı ¨ve groups continued to lose body weight and were
subsequently euthanized over the period of 7–12 days p.i when
their body weight loss was greater than 30% of the pre-challenge
weight (Fig. 4C). In contrast 100% of the pMCE321 vaccinated
animals recovered and survived beyond day 12 p.i. Viremia on
day 5 after i.n. infection was also measured in five unvaccinated
animals infected with the CHIKV virus (mean titer log10
1.5 PFU/ml 60.42), and vaccinated animals (mean titer log10
0.58 PFU/ml 60.17). The vaccinated animals had significantly
lower viremia (p, 0.001) with no signs of infection and remained
apparently healthy (Fig. 4D).
Histopathologic evaluation of CHIKV-challenged mice
Histopathological studies were conducted in vaccinated and
naı ¨ve animals in the brain for neurological manifestations, liver
(the initial site of virus replication), lungs (the portal of entry
alternate to skin), heart and kidneys.
Brain. The CHIKV-infected brains of the naı ¨ve mice showed
severe spongiform changes and a large number of apoptotic bodies
and microglial nodule formation in the external granular layer of
the cerebral cortex. We also observed moderate edema. The
Capsid-vaccinated mice showed severe hemorrhage in cerebral
cortex and microglial infiltration in lamina pyramidalis externa.
Modicum microglial and minimal edema was seen in the CHIKV-
infected brains of pMCE321-immunized mice suggesting
immunization decreased CHIKV-mediated pathology of the
brain (Fig. 5A).
Heart. The histopathological analysis of the heart tissue in
naı ¨ve mice showed severe myocardial degeneration/necrosis. Also,
infiltration of inflammatory cells between myocardial fibers was
seen. Most of the myocardium was destroyed in Capsid-
immunized mice with punctuated hemorrhage. A compact and
orderly arrangement of myocardium was evident in the
pMCE321-immunized mice and nuclei of the cells were clearly
visible (Fig. 5C).
Liver. As expected in the CHIKV-infected naı ¨ve group, severe
degeneration/necrosis presented in the centrilobular region. Dilation
and hyperemia of sinus hepaticus, lymphocytic infiltration, and
thrombus formation in the lumen was also seen in this group.
Hepatocyte vacuolar degeneration and focal necrosis around the
central vein were observed in the Capsid-immunized group. Hepatic
sinus dilation and lymphocytic infiltration were seen in the Capsid-
immunized group. In contrast the pMCE321-immunized group did
not show any severe pathologic abnormalities (Fig. 5C).
Figure 4. CHIKV DNA vaccination and infection. (A&B) Analysis of proinflammatory cytokines (TNF-a and IL-6) in CHIKV vaccinated and infected
mice. Cytokine levels (pg/ml) were assayed by ELISA from the cell free sera from 10 days post infection. These data represent the average 3 wells/
mouse and standard deviations of 4 mice. (C) Percent survival in CHIKV-challenged mice. Similar results were observed in 2 independent experiments
with at least n=10 per group for each experiment. (D) The viremia, 5 day after challenge, as measured by a plaque assay. Mice immunized with pVax1
(control) or immunized pMCE321 (vaccine) were challenged with the PC-08 CHIKV strain at a dose of 7 log10 PFU by the intranasal route. Data are
mean 6 SEM of 5 animals.
doi:10.1371/journal.pntd.0000928.g004
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epithelial cell exfoliation, and inflammatory infiltration around
bronchioles were observed. Furthermore, alveolar sacs were
observed to be filled with exfoliative and inflammatory cells. A
similar pathology was observed in the capsid-immunized group, in
addition, and an alveolus filled with red blood cells and thrombosis
was observed in the pulmonary venule. In contrast, no significant
pathologic changses were observed in the lungs of CHIKV-
infected pMCE321-immunized mice (Fig. 5C).
Kidney. Microscopic observation of sections using hematoxylin-
eosin staining revealed degeneration/necrosis of renal tubular cells in
the naı ¨ve mice, which caused renal tubular lesions. Hyaline casts were
observed. Also, severe hemorrhage and inflammatory cell infiltration
was seen between the renal tubules. In the Capsid-immunized mice,
renal tubular cells showed severe degeneration/necrosis, more
hemorrhage and infiltration of inflammatory cell. However, in the
pMCE321-immunized mice very few renal tubular cells degenerated,
hemorrhage and inflammatory cells infiltration was minimal
compared with those of the naive group (Fig. 5C).
CHIKV DNA vaccination is immunogenic in nonhuman
primates
Nonhuman primate studies were performed to determine
whether CHIKV DNA vaccination with pMCE321 could elicit
cellular as well as humoral responses, characterized by the
elicitation of nAb responses. Four rhesus macaques were vaccinated
with pMCE321 DNA delivered by in vivo EP. As negative controls,
three monkeys were vaccinated with the pVax1 control vector. The
animals were then monitored for the development of CHIKV
Envelope-specific CD8
+ T-lymphocyte and nAb responses. Two
weeks after the fifth DNA immunization, cells and serum were
collected and tested for immunogenicity. Three of the four CHIKV
pMCE321 DNA-immunized monkeys had detectable envelope -
specific functional CTL activity as measured by IFN-c ELIspot
(Fig. 6A). The control plasmid-immunized monkeys remained
negative throughout the course of the experiment. Furthermore, of
the four monkeys immunized with the pMCE321 DNA vaccine, all
four monkeys developednAb titers.Theseaveraged 570 andranged
from 80-1,280 titers (Fig. 6B).
Figure 5. Histopathology analysis of CHIKV challenged mice. (A) H&E stained sections of Brain. pMCE321 vaccinated mice showed no severe
pathological changes and showed only minimal microglial formation. Capsid immunized mice group showed severe hemorrhage and microglia
formation similar to the naı ¨ve group. (B) H&E stained sections of Heart, Liver, Kidney and Lungs. Envelope vaccinated group showed minimal or no
pathological changes in the organs. The naı ¨ve group showed severe pathological changes indicative of virus infection and the Capsid DNA
immunized group showed similar pathological changes to the naı ¨ve group. Representative data are shown from 2 mice/group.
doi:10.1371/journal.pntd.0000928.g005
Chikungunya DNA Vaccination
www.plosntds.org 9 January 2011 | Volume 5 | Issue 1 | e928CHIKV induces neutralizing antibodies in humans and
correlates with HI-Ab response during infection
We next compared macaque nAb titers with those observed in
human patient convalescent sera. Understanding the correlates of
immunity during CHIKV infection is likely important for the
rational design and development of an effective vaccine. While it
is clear that a nAb response appears to be critical for protection
against CHIKV infection, as with many infectious diseases like
influenza and hepatitis, the levels required to induce sterilizing
immunity or protection from disease-related morbidity are
currently unknown. Therefore, we tested serum samples from
CHIKV-infected individuals to measure levels of nAb activity.
Among the thirty patients tested in this study, sixteen patients
(53%) showed nAb titers to CHIKV, (titers above 20 titers were
considered as positive; [41]), ranging from 40–640 titers (Fig. 7A).
Further, the presence of HI Abs to arboviruses including CHIKV
was observed in seroepidemiological studies [18,32]. However the
importance of HI during active CHIKV infection is not well
understood. During the recent outbreak investigation, HI Abs
were observed in eighteen (60%) of the thirty patients tested in
the study. The HI titers varied from 20-1,280 titers (Fig 7B).
Indeed, the HI titer also directly correlated with the levels of nAb
in CHIKV infected patients (r=0.9424; p,0.001) (Fig. 7C),
suggesting that the neutralizing and HI antibodies to CHIKV
correlate with the ability of the host to clear the infectious virus
during the course of natural infection. The neutralization titer
was defined as the highest dilution of serum that prevented virus
propagation as determined by CPE (Fig. 7D). Interestingly, the
post-infection nAb titers in convalescent humans were in the
same range as the vaccine- induced titers we observed in
macaques suggesting its value as a potential model for CHIKV
vaccine development.
The mouse and primate immunological data taken together
demonstrate that vaccination with pMCE321 induces a strong
CD8
+ T cell-mediated cellular response as well as a humoral
response (nAb and HI titers) capable of protecting the animals
against a lethal challenge. In convalescent human samples we
report the presence of significant nAb titers. Taken together, the
data is suggestive of the role of antibody responses in protecting
against CHIKV.
Discussion
CHIKV is an emerging pathogen and an important public
health concern [2,5,12,13,49]. Since no licensed vaccine or
treatment is available for the pathogen, there is an urgent need
for an effective vaccine [30]. In this report, we describe the
development of a DNA vaccine construct from our laboratory that
expresses three of the CHIKV envelope proteins (E3, E2, and E1),
is immunogenic in mice and nonhuman primates, provides
protection in mice, and drives neutralizing titers in primates
similar to those observed in human patient convalescent sera.
During the recent outbreak in India, sera were obtained from
human patients with suspected CHIKV disease. All patients were
from outbreak areas and a total of thirty sera were randomly
selected and included in this study. However, the clinical picture
reported herein had a different pattern with respect to previous
reports [50]; this cohort had less severe disease symptoms and the
reasons attributed to this could be multifactorial, such as the time
of sample collection, the magnitute and types of immune responses
mounted by these individuals, and the presence of pre-existing
immunity in the outbreak area. RT-PCR confirmed the laboratory
diagnosis and most of the patients in the study group were found to
be positive, additionally having neutralizing/HI Abs to CHIKV.
Virus isolation was successfully accomplished from the serum of a
Figure 6. Immunogenicity of CHIKV DNA vaccine in nonhuman primates. (A) IFN-c ELISpot assay results presented are from individual
macaques 2 weeks after the fifth immunization against pMCE321 administered vaccine. PBMCs harvested from animals immunized with pMCE321
were used in the IFN-c assay. We also tested PBMCs that were depleted of CD8
+ T cells by magnetic bead separation before in vitro stimulation. The
PBMCs were incubated in the presence of the following stimulators and controls: R10 medium (negative control), Con A (5 mg/ml positive control),
and 10 mg/ml CHIKV peptide mix. Data are presented as the SI (experimental counts/spontaneous counts), where the spontaneous count wells are
from the R10-negative control wells as described in Materials and Methods. Values represent the mean of triplicate cultures and are representative of
three independent experiments. (B) nAb titers from sera of DNA vaccinated monkeys are shown. The pMCE321 DNA vaccine construct induced nAb
responses ranging from 80-1,280 titers and mimicked those induced in convalescent patient sera.
doi:10.1371/journal.pntd.0000928.g006
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CHIKV by RT-PCR amplifying the partial region of the E2 gene.
Further, phylogenetic tree analysis with this sequence revealed a
similarity to the Chikungunya strain Ross.
The importance of nAb against a viral infection has been well
established and was reported earlier in a recent CHIKV study and
also an RRV study, a virus that is similar to CHIKV [32,51]. Viral
clearance was associated with the rapid induction of nAb in the
Figure 7. Antibody-mediated neutralization and Hemagglutination Inhibition from CHIKV-infected patient serum. nAb titers (A) and
Hemagglutination Inhibition (HI) antibody responses (B) in patient sera (SRMC-1 to SRMC-30) to CHIKV. Similar results were observed in 2
independent experiments. There is a positive correlation exists between nAb and HI on CHIKV infected patients (C). These relationships were
evaluated using the Spearman correlation test using the Prism 5 Graph Pad software. Neutralization of CHIKV infectivity with patient serum (D). The
IC50 is defined as the reciprocal of the antiserum dilution at which CHIKV virus entry is 50% inhibited (dashed line). Similar results were observed in 2
independent experiments.
doi:10.1371/journal.pntd.0000928.g007
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infection [52]. The same concepts may also extend to immunity to
CHIKV infection. For example, previous reports in populations
with high levels of nAb against CHIKV showed low infection
rates, possibly due to protective immunity due to prior exposures,
thus resulting in subsequent protective immunity [2,17,48]. For
instance, a study in northern Malaysia found that 35% of adults
had nAbs against CHIKV even though there were no reports of a
CHIKV outbreak in Malaysia, during this period of time.
Furthermore, serologic surveys in India not linked to a recognized
outbreak found a prevalence of 4.4% in the Calcutta metropolis
and 15.3% in Andaman and Nicobar Island [7,16,53]. Hence, it is
likely that nAb aid in the reduction of symptoms either by aiding
in clearing the virus or by preventing the pathological damage
caused by the virus. In the current study, the range of nAb titers
observed in the study cohort ranged between 40 and 640.
Similarly, the HI titers induced in patients were in parallel with the
neutralizing titer with HI titers ranging from 20 to 1,260.
The findings of significant nAb titers in human patient sera
during active infection encouraged us to compare the capacity of
our CHIKV DNA vaccine to generate nAb. Our previous CHIKV
DNA vaccine consisting of the co-delivery of two different plasmids,
pCHIKV-E1 and pCHIKV-E2, was capable of inducing levels of
neutralizing and HI titers; pCHIKV-E2 induced the production of
nAband pCHIKV-E1elicitedHIAbs responseinimmunizedmice.
These findings led us to combine the predominant genes that
constitutetheentireCHIKVenvelopeinasingleenvelopeconstruct
(pMCE321) for vaccination. We envisioned such an approach may
lead to simultaneously increased cellular responses and humoral
responses and likely inducing both neutralizing and hemagglutina-
tioninhibition Abs. Indeed,thenovel envelope constructpMCE321
vaccine drove the cellular response to both E1 and E2 glycoproteins
and the magnitude of this response was higher than that seen with
individual E1/E2 gene constructs. Moreover, the humoral
responses to pMCE321 were also increased when compared to
that of the individual pCHIKV-E1 and pCHIKV-E2 constructs.
To assess the protective efficacy of this novel vaccine construct
capable of generating both strong cellular and humoral immunity,
we conducted a CHIKV challenge study in mice and observed
that the PC-08 strain of virus was pathogenic in mice. Specifically,
we observed a reduction in body weight, lethargy, hind limb
weakness and high levels of proinflammatory cytokines such as IL-
1b, TNF-a and IL-6 [31,40]. Following challenge with CHIKV,
all of the naı ¨ve mice showed severe weight loss from 1-3 days p.i.
and showed clinical symptoms like lethargy and hind limb
weakness by day 6. However, none of the envelope-based
vaccine-immunized mice showed clinical symptoms as pro-
nounced as in the unvaccinated mice. While control mice
continued to lose weight over the course of the study and had to
be euthanized, the Env-immunized mice rapidly regained weight
after the initial 3 days and returned to their normal, pre-challenge
state. Overall, these data showed that the new envelope-based
vaccine construct pMCE321 was highly effective at protecting
against morbidity and mortality in this model. Furthermore, our
study also demonstrated an inverse relationship between vaccina-
tion and the resulting viremia. Interestingly, we observed a
reduction in the amount of virus in the vaccinated mice compared
to the unvaccinated mice post-challenge. Similarly, the histopath-
ological evaluation of tissues from the brain, liver, heart, lung and
kidney in immunized mice showed minimal or no damage when
compared to naı ¨ve infected mice. Furthermore, Capsid-immu-
nized mice exhibited symptoms of morbidity as well as mortality
likely due to the lack of induction of nAb responses. This
protective efficacy may likely be attributed to the high titers of nAb
produced in the vaccinated animals similar to the findings in
humans where high neutralizing titers have been correlated to
better disease prognosis and protection [15,17,32,54].
Due to the induction of strong immunity and protection in
mice, we next wanted to assess whether the envelope DNA vaccine
(pMCE321) was immunogenic in nonhuman primates. Four
rhesus animals were immunized and the cellular and humoral
responses were measured. Similar to the immune responses
observed in vaccinated mice, CHIKV envelope-specific T cell
responses were induced as well as nAb responses in the nonhuman
primate cohort. Importantly, the range of neutralization titers
observed in these animals was similar to the levels observed in
humans during active CHIKV infection. These data demonstrate
that the pMCE321 DNA vaccine is immunogenic in nonhuman
primates, and was capable of producing titers of nAb which are
thought to be protective in humans against disease.
In summary, there are several important findings in this
manuscript. We report the isolation of a new isolate of CHIKV
from the southern regions of India which we have named PC-08.
T h i si s o l a t ei sc y t o p a t h i ci ns e v e r a lc e l ll i n e sa sw e l la sp r i m a r y
immune cells. The virus can induce pathogenesis in a mouse
challenge model through i.n. challenge and thus should provide a
useful in vivo model for further study. Furthermore, this viral stock
allowed us to scale up a Neutralization assay for CHIKV study. We
also report development of a novel single-plasmid envelope-based
DNA vaccine; pMCE321 is protective in the mouse challenge model
and drives relevant titers of nAb in a macaque model system. Further
study of this novel vaccine and protective immunity is warranted.
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